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April 14, 2009:1383–7n the article by Skyler JS, Bergenstal R, Bonow RO, et al., “Intensive Glycemic Control and the Prevention of
ardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials: A Position Statement of the
merican Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the
merican Heart Association,” which published ahead of print on December 17, 2008, and appeared in the January 20, 2009,
ssue of the journal (J Am Coll Cardiol 2009;53:298–304), a correction should be made to Richard Bergenstal’s disclosure
f potential financial dualities of interest information.
he second full paragraph in the right-hand column on p. 303 should be replaced with the following information:
R.B. participates in clinical research or has served on a scientific advisory board for Amylin, Merck, Pfizer, ResMed,
aleritas, Eli Lilly, Novo Nordisk, sanofi-aventis, MannKind, Intuity, Roche, LifeScan, Abbott, Bayer, and Medtronic. R.B.
eceives no personal compensation for these activities; all contracts are through the nonprofit Park Nicollet Institute. R.B.
olds stock in Merck through a family inheritance and is an officer within the American Diabetes Association.
doi:10.1016/j.jacc.2009.03.002
onaka A, Stugaard M, Ueda O, Hara H, Shimada T, Shiotani H. Fluorodeoxyglucose–positron emission tomography
ifferentiating thrombus from tumor in the left ventricle. J Am Coll Cardiol 2009;53:894.
he author affiliations should have been listed as:
Akiko Nonaka, MD,* Marie Stugaard, MD,* Osamu Ueda, RT,† Hideyuki Hara, RT,† Temiko Shimada, MD,‡
ideyuki Shiotani, MD§
From the *Cardiology Department, †Radiology Department, ‡Department of Thoracic Oncology, Hyogo Cancer Center,
kashi, Japan; and the §Department of Preventive Medicine, Graduate School of Health Sciences, Kobe University, Kobe,
apan.
doi:10.1016/j.jacc.2009.03.003
